Skip to main content

Market Overview

Alexion (ALXN) and Celgene (CELG) Ratings Discusses as Revlimid Maintenance Has Last Showing Before Approval

Share:

In a Piper Jaffray research report this morning Alexion (NasdaqGS: ALXN) and Celgene (NasdaqGS: CELG) are both reviewed as they are awaiting approval for Soliris and Revlimid Maintenance respectively.

Alexion has an Overweight rating with a price target of $86.

Alexion closed Monday at $72.73.

Celgene has an Overweight rating with a price target of $81.

Celgene closed Monday at $60.96.

 

Related Articles (ALXN + CELG)

View Comments and Join the Discussion!

Posted-In: Alexion Celgene Piper JaffrayAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com